Clinical Trial Update: Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

View source ↗

Summary

The long-term follow-up study to evaluate safety and efficacy of FBX-101 in Krabbe disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Krabbe Disease

Drugs mentioned

• FBX-101

Snippet

Sponsor: Forge Biologics, Inc | Conditions: Krabbe Disease | Status: TERMINATED